CoRAP update 2026–2028 flags 27 substances for REACH evaluation

The European Chemicals Agency (ECHA) has published its CoRAP update 2026–2028, identifying 27 substances for evaluation under REACH, with immediate implications for manufacturers, downstream users and compliance teams across the chemicals value chain. The plan, adopted on 24 March 2026, prioritises substances suspected of posing risks to human health or the environment, with evaluations led by eight Member State authorities.

Scope and timeline of the CoRAP update 2026–2028

The CoRAP update 2026–2028 includes 17 substances scheduled for evaluation in 2026, nine in 2027 and one in 2028. Eight substances are newly added, while 20 were carried over from the previous plan. Three evaluations have been postponed to allow for additional data submissions, reflecting ongoing regulatory scrutiny and data gaps. Substance evaluation under REACH aims to clarify potential risks where existing data is insufficient. Authorities may request further information from registrants, which can lead to regulatory risk management measures such as restrictions or authorisation requirements.

Key substances and risk drivers

The CoRAP update 2026–2028 highlights several recurring hazard profiles. These include reproductive toxicity, endocrine disruption, persistence and bioaccumulation, and mobility in the environment. Examples include: Tetramethylthiuram monosulphide, flagged for mutagenicity and worker exposure risks. Methyl N-{[dimethoxy(methyl)silyl]methyl}carbamate, identified as a potential endocrine disruptor affecting both human health and the environment. Multiple benzotriazole-derived UV stabilisers, assessed for persistence, mobility and widespread environmental exposure. High production volumes, wide dispersive uses and consumer exposure are key factors driving prioritisation.

Implications for industry and supply chains

For industry stakeholders, the CoRAP update 2026–2028 signals heightened regulatory attention on substances used in coatings, plastics, fuels and specialty chemicals. Companies must proactively review substance portfolios, ensuring dossiers are up to date and aligned with evolving hazard data. Downstream users, including formulators and product manufacturers, should assess supply chain dependencies and consider substitution strategies where risks may escalate. Investors and insurers may also factor CoRAP listings into risk assessments. ECHA encourages registrants to engage early with evaluating authorities, particularly for substances scheduled in 2026, to clarify concerns and avoid delays.

Compliance actions to consider

Organisations should: Monitor evaluation progress and potential data requests Strengthen internal data collection on exposure and use patterns Prepare for possible regulatory outcomes, including restrictions

Outlook for REACH enforcement

The CoRAP update 2026–2028 reflects a continued shift towards addressing complex hazard profiles such as persistent and mobile substances and endocrine disruptors. This aligns with broader EU chemicals strategy goals and signals further regulatory tightening in the coming years.